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Velafermin (CG53135-05 or recombinant human ﬁbroblast
growth factor-20) is under investigation for the prevention of
oral mucositis (OM). OM is a common side effect in patients
(pts) receiving high-dose chemotherapy (HDCT) with or with-
out total body irradiation (TBI) as conditioning regimen for
AHSCT. Preclinical studies have demonstrated that velafermin
promotes epithelial and mesenchymal cell proliferation in vitro
and that a single dose of velafermin had activities in reducing
the severity and duration of OM as effective as multiple doses.
Previous clinical data suggested that velafermin could be safely
given at doses up to 0.2 mg/kg. The objectives of this phase II
trial were to evaluate the safety and efﬁcacy of velafermin in
preventing severe OM from approximately 200 pts undergoing
HDCT with or without TBI for an AHSCT in the US. Patients
were equally randomized to one of four arms: placebo, or
velafermin 0.03, 0.1 or 0.2 mg/kg. Pts received a single intra-
venous dose of velafermin or placebo 24-36 hrs after completion
of the stem cell infusion and were monitored daily until they
were discharged from the hospital or until neutrophil engraft-
ment established (deﬁned as ﬁrst day of absolute neutrophil
counts 500/ in this study). The primary end point was the
incidence of OM (World Health Organization (WHO) score of
grade 3 or 4). Secondary end points included duration of severe
OM, area under the curve of all OM, days with alternative
nutrition, and narcotic analgesic use. Patient enrollment was
completed with 212 pts randomized. Approximately 2/3 were
multiple myeloma pts receiving high dose melphalan as condi-
tioning regimen and 1/3 of them were lymphoma pts. Less than
10% of pts had TBI as part of their conditioning regimen.
Preliminary blinded aggregate data from 160 pts indicated that
study drug was generally well tolerated. 30% of pts did not
develop any OM and 32% pts developed grade 3/4 OM with a
duration of 4.8  3.7 (mean  sd) days among the pts with
severe OM. Most adverse events (AE) were mild to moderate in
severity with most frequent serious AEs being neutropenic
fever, pneumonia and pyrexia. The trial was monitored by a
Data Safety Monitoring Board (DSMB). The results of the
primary end point of grade 3/4 OM from each treatment arm or
placebo as well as 30-day safety information from all pts will be
reported.
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Invasive aspergillosis (IA) is a common cause of infection-related
mortality in hematopoietic stem cell transplant (HSCT) recipients,
despite appropriate therapy. Factors inﬂuencing outcomes have
not been fully elucidated. To determine prognostic factors associ-
ated with mortality we retrospectively reviewed all cases of proven
and probable IA diagnosed in HSCT recipients at the Fred
Hutchinson Cancer Research Center (FHCRC) from 1st Jan 1990
to 31st Dec 2004. All-cause and attributable mortality were re-
corded. Prognostic factors identiﬁed in univariate analysis (P 
.10) were further analyzed using a Cox multiple regression model.
All variables except those occurring before HSCT were modeled as
time dependent. 408 cases were identiﬁed: 238 proven and 170
probable IA. The probability of overall mortality at 1 year after
diagnosis was 70% in patients diagnosed from 2002 to 2004 versus
86% among those diagnosed prior to 2002 (P  .0001). Cord
blood as stem cell source (HR  3.7 [1.0-13.2]), severe pulmonary
function test abnormality pre-HSCT (2.3 [1.2-4.2]), increased cre-
atinine (2.9 [1.9-4.3]) and bilirubin (6.2 [4.4-8.7]) at time of diag-
nosis of IA, monocytopenia (2.3 [1.6-3.2]), CMV disease (1.4 [1.0-
1.8]), receipt of antithymocyte globulin (2.2 [1.5-3.3]),
disseminated IA (2.0 [1.4-2.7]), and IA later after HSCT (	40
days) (2.8 [2.0-4.1]) were independently associated with increased
all-cause mortality; receipt of non-myeloablative HSCT (0.5 [0.3-
0.7]) was independently associated with decreased mortality. The
probability of mortality attributable to IA at 1-year was 26% in
patients diagnosed from 2002 to 2004 versus 49% among those
diagnosed prior to 2002 (P  .007). Mismatched HSCT (2.1
[1.2-3.7]), increased creatinine (3.3 [1.8-6.1]) and bilirubin (5.5
[3.3-9.3]), receipt of antithymocyte globulin (2.3 [1.2-4.1]), dissem-
inated IA (4.0 [2.5-6.3]) and IA later after HSCT (2.4 [1.2-4.0])
were independently associated with increased attributable mortal-
ity; non-myeloablative HSCT (0.3 [0.1-0.8]) and receipt of vori-
conazole therapy (0.4 [0.2-0.8]) were independently associated with
decreased mortality. In this study we have demonstrated a signif-
icant decline in mortality in patients diagnosed with IA following
HSCT in the time period 2002-2004, compared with prior to
2002. This ﬁnding has coincided with increased use of non-my-
eloablative conditioning regimens and voriconazole; two factors we
have identiﬁed to be protective.
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